pharma · Obesity, Overweight · Type 2 Diabetes
Eli Lilly and
Eli Lilly Co.
Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 1
Company details
- Status
- Public
- HQ
- Lilly Corporate Center, Indianapolis, Indiana 46285, US
- Founded
- 1876
- Employees
- 55,860
- Programs
- 107
- Drugs
- 99
- Patents
- 0
SELPERCATINIB, SELPERCATINIB
Approved · small molecule · Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;
SELPERCATINIB, SELPERCATINIB for Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration; is a Approved program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Internal code LOXO-RET-18037
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eli Lilly Co.
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;
- Status
- active
- Trials
- 1